Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 16.6%
Concerns1
- Slow revenue growth of 3.6% CAGR over 5 years
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ8.81 K Cr | β | βΉ2.28 K Cr | β | β | 18.5% | 10.7% | 30.6% |
| Mar 2024 | βΉ7.96 K Cr | β | βΉ1.75 K Cr | β | β | 16.6% | -12.0% | 54.1% |
| Mar 2023 | βΉ9.05 K Cr | β | βΉ1.13 K Cr | β | β | 12.1% | 2.5% | -26.4% |
| Mar 2022 | βΉ8.83 K Cr | β | βΉ1.54 K Cr | β | β | 17.6% | 22.3% | -8.5% |
| Mar 2021 | βΉ7.22 K Cr | β | βΉ1.69 K Cr | β | β | 22.1% | 8.1% | 33.3% |
| Mar 2020 | βΉ6.68 K Cr | β | βΉ1.26 K Cr | β | β | 20.1% | 16.9% | 58.0% |
| Mar 2019 | βΉ5.71 K Cr | β | βΉ800.00 Cr | β | β | 14.6% | 8.2% | 11.7% |
| Mar 2018 | βΉ5.28 K Cr | β | βΉ716.00 Cr | β | β | 14.7% | 16.1% | -18.9% |
| Mar 2017 | βΉ4.55 K Cr | β | βΉ883.00 Cr | β | β | 20.1% | 16.3% | 26.1% |
| Mar 2016 | βΉ3.91 K Cr | β | βΉ700.00 Cr | β | β | 19.4% | 27.3% | 90.2% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 9,246 |
| Total Expenses | 6,900 |
| EBIT / Operating Profit | 2,346 |
| OPM % | 25% |
| Other Income | 708 |
| Finance Costs | 63 |
| Depreciation & Amortisation | 277 |
| Profit Before Tax | 2,714 |
| Tax % | - |
| Net Profit / PAT | 2,443 |
| EPS (βΉ) | 204.32 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Alkem Laboratories Limitedthis co. | βΉ70.09 K Cr | βΉ8.81 K Cr | 31.40 | 5.13 | 32.97 | 10.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |